Thomas Marbury - Publications, H-index & Citations

Thomas Marbury

Orlando Clinical Research Center

47H指数

258论文数

7.8K被引数

收录论文 70

发表时间

Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial Fedratinib在成人中度及重度肝功能不全患者中的药代动力学、安全性和耐受性：FEDR-CP-001期1临床试验结果

Cancer Chemotherapy and Pharmacology

IF2.3

2025-07-02

PREAI

Yizhe Chen; Richard A. Preston; Thomas Marbury; William B. Smith; Massimo Attanasio; Mark Thomas; Michael Thomas; Bing He; Yongjun Xue; Atalanta Ghosh; Gopal Krishna; Ken Ogasawara

Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment Navitoclax的药代动力学和安全性研究（肝功能不全患者）

CLINICAL PHARMACOKINETICS

IF4

2025-03-27

PREAI

Patel, Maulik; Potluri, Jalaja; Marbury, Thomas; Lawitz, Eric; Rondon, Juan Carlos; Hoffman, David M.; Siddani, Satya R.; Marsh, Kennan C.; Kim, Elaine J.; Uddin, Muhammad Erfan; Menon, Rajeev M.; Polepally, Akshanth R.

The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-11-22

OAAI

Yeung, Sam Au; Stein, Daniel S.; Marbury, Thomas C.; Usansky, Helen

Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial 蛋白C激活剂AB002在血液透析终末期肾病患者中的安全性和耐受性: 一项随机2期试验

COMMUNICATIONS MEDICINE

IF6.3

2024-07-26

OAAI

Verbout, Norah G.; Lorentz, Christina U.; Markway, Brandon D.; Wallisch, Michael; Marbury, Thomas C.; Di Cera, Enrico; Shatzel, Joseph J.; Gruber, Andras; Tucker, Erik I.

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment 减少肝损害的研究，以评估zavegepant的药代动力学和安全性，并告知肝损害的剂量建议

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-07-16

OAAI

Bhardwaj, Rajinder; Donohue, Mary K.; Madonia, Jennifer; Morris, Beth; Marbury, Thomas C.; Matschke, Kyle T.; Croop, Robert; Bertz, Richard; Liu, Jing

Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis 接受血液透析的终末期肾病患者中维奈托克的药代动力学研究

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-11-21

PREAI

Noorani, Behnam; Menon, Rajeev M.; Chen, Xin; Marsh, Kennan C.; Huang, Weize; Gupta, Shelly; Dobkowska, Edyta; Marbury, Thomas; Salem, Ahmed Hamed

A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib I期，开放标签，单剂量研究，以评估肝功能损害对futibatinib药代动力学和安全性的影响

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2023-08-08

OAAI

Gao, Ling; Yamamiya, Ikuo; Pinti, Mark; Rondon, Juan Carlos; Marbury, Thomas; Tomlinson, Gareth; Makris, Lukas; Hangai, Nanae; Wacheck, Volker

Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects

CANCER RESEARCH

IF16.6

2023-04-14

PREAI

Gao, Ling; Yamamiya, Ikuo; Pinti, Mark; Rondon, Juan Carlos; Gareth, Thomas Marbury; Tomlinson, Gareth; Makris, Lukas; Hangai, Nanae; Wacheck, Volker

Brigatinib pharmacokinetics in patients with chronic hepatic impairment 布格替尼在慢性肝损害患者中的药代动力学

INVESTIGATIONAL NEW DRUGS

IF2.7

2023-04-13

OAAI

Hanley, Michael J.; Kerstein, David; Tugnait, Meera; Narasimhan, Narayana; Marbury, Thomas C.; Venkatakrishnan, Karthik; Gupta, Neeraj

Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study 多剂量Alpelisib在中度或重度肝损伤参与者中的药代动力学和安全性: 1期，开放标签，平行组研究

JOURNAL OF CANCER

IF3.2

2023-01-01

OAAI

Marbury, Thomas; El-Hashimy, Mona; Blumenstein, Lars; Letellier, Franck; Sengupta, Tirtha; Lorenzo, Sebastien; Preston, Richard Alfred

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2022-09-20

OAAI

Dowell, James A.; Marbury, Thomas C.; Smith, William B.; Henkel, Tim

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam 轻度或中度肝损害对risdiplam药代动力学的影响

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-04-01

OAAI

Kletzl, Heidemarie; Ajmi, Hassan; Antys, Izabela; Heinig, Katja; Jaber, Birgit; Marbury, Thomas C.; Young, Annie; Gunther, Andreas

Effect of hepatic impairment on tepotinib pharmacokinetics

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Marbury, T.; Yalkinoglu, Oe.; Becker, A.; Krebs-Brown, A.; Bytyqi, A.; Port, A.; Strotmann, R.

Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-06-18

OAAI

Chen, Xinhui; Cui, Xiaoming; Pognan, Nathalie; Quinlan, Michelle; Kapoor, Shruti; Rahmanzadeh, Gholamreza; Giovannini, Monica; Marbury, Thomas C.

Effect of severe renal impairment on the pharmacokinetics of brigatinib 严重肾损害对布格替尼药代动力学的影响

INVESTIGATIONAL NEW DRUGS

IF2.7

2021-03-20

OAAI

Gupta, Neeraj; Hanley, Michael J.; Kerstein, David; Tugnait, Meera; Narasimhan, Narayana; Marbury, Thomas C.; Venkatakrishnan, Karthik

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients

KIDNEY INTERNATIONAL REPORTS

IF5.7

2021-03-01

OAAI

Maruyama, Sonomi; Marbury, Thomas C.; Connaire, Jeffrey; Ries, Daniel; Maxwell, William; Rambaran, Curtis

Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial

DIABETES OBESITY & METABOLISM

IF5.7

2021-02-16

PREAI

He, YanLing; Pachori, Alok; Chen, Ping; Ma, Shenglin; Mendonza, Anisha E.; Amer, Ahmed; Marbury, Thomas C.; Hinder, Markus

A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-10-26

PREAI

Tatosian, Daniel A.; Yee, Ka Lai; Zhang, Zufei; Mostoller, Kate; Paul, Erina; Sutradhar, Santosh; Larson, Patrick; Chhibber, Aparna; Wen, Jianzhong; Wang, Ya-Juan; Lassman, Michael; Latham, Andrew H.; Pang, Jianmei; Crumley, Tami; Gillespie, Anne; Marricco, Nadia Cardillo; Marenco, Ted; Murphy, Matthew; Lasseter, Kenneth C.; Marbury, Thomas C.; Tweedie, Donald; Chu, Xiaoyan; Evers, Raymond; Stoch, S. Aubrey

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-01-23

OAAI

Bhagunde, Pratik; Colon-Gonzalez, Francheska; Liu, Yang; Wu, Jin; Xu, Shiyao Sherrie; Garrett, Graigory; Jumes, Patricia; Lasseter, Kenneth; Marbury, Thomas; Rizk, Matthew L.; Lala, Mallika; Rhee, Elizabeth G.; Butterton, Joan R.; Boundy, Keith

Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2019-03-04

OAAI

Sheetz, Matthew; Barrington, Philip; Callies, Sophie; Berg, Paul H.; McColm, Juliet; Marbury, Thomas; Decker, Brian; Dyas, Gregory L.; Truhlar, Stephanie M. E.; Benschop, Robert; Leung, Donmienne; Berg, Jolene; Witcher, Derrick R.

研究方向